Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.
Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.
Syndax Pharmaceuticals (SNDX) granted new Chief Financial Officer Aaron A. Ondrey an inducement stock option covering up to 270,000 common shares. His appointment took effect November 9, 2026, following its announcement on November 2, 2026.
The option has an exercise price of $9.55 per share, matching the stock's November 9 closing price. It vests over four years: 25% on the first anniversary of the vesting commencement date, followed by 1/48th of the underlying shares monthly over 36 months. Vesting requires continued service through each applicable date. The board approved the employment inducement award under Nasdaq Listing Rule 5635(c)(4).
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement stock options covering up to 213,500 common shares to five new employees under its 2023 Inducement Plan.
The options vest over four years: 25% of the underlying shares vest on the first anniversary of the vesting commencement date, followed by 1/48th of the underlying shares monthly over the next 36 months. Vesting is subject to each employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event and live webcast on December 14, 2026, during the ASH Annual Meeting.
The event runs from 7:00–8:30 a.m. CT / 8:00–9:30 a.m. ET. Management and medical opinion leaders will discuss data presented at the meeting. The webcast and a limited-time replay will be available in the Investor section of the company's website.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced acceptance of 19 abstracts for the ASH Annual Meeting taking place December 12–15, 2026, in New Orleans. The program includes 14 revumenib abstracts, seven selected for oral presentation, and five axatilimab abstracts.
Revumenib presentations cover combinations for newly diagnosed acute myeloid leukemia, outcomes before and after stem cell transplantation, post-transplant maintenance, and treatment for measurable residual disease, meaning leukemia detectable after treatment. Other presentations address real-world treatment outcomes. Axatilimab presentations include long-term efficacy and safety from the Phase 2 AGAVE-201 trial in chronic graft-versus-host disease. Syndax will host an investor event and webcast on December 14, 2026, from 7:00–8:30 a.m. CT to discuss data presented at the meeting.
Syndax Pharmaceuticals (Nasdaq: SNDX) appointed Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026, succeeding Keith A. Goldan.
Goldan is retiring from the CFO position and will remain with the company through the end of 2026 to support the transition. Ondrey brings more than 25 years of financial and operational leadership experience across biotechnology.
Most recently, Ondrey was CFO of Beren Therapeutics, overseeing finance, investor relations and manufacturing operations. Previously, he was CFO of Rocket Pharmaceuticals and CFO and Senior Vice President at Mirati Therapeutics. At Mirati, he supported KRAZATI commercialization and played a role in its acquisition by Bristol Myers Squibb in January 2024. His earlier leadership roles included positions at Arena Pharmaceuticals, Alexion Pharmaceuticals and Regeneron Pharmaceuticals.
Syndax Pharmaceuticals (Nasdaq: SNDX) reported third-quarter 2026 revenue of $83.3 million, up 82% from the same period last year. Revuforj net revenue reached $60.7 million, up 90% year over year. Niktimvo contributed $22.6 million in collaboration revenue. Net loss attributable to common stockholders narrowed to $49.4 million, or $0.55 per share, from $60.7 million, or $0.70 per share.
Cash and investments totaled $551.1 million at September 30. Syndax maintained its approximately $400 million full-year research, development and administrative expense outlook, excluding estimated non-cash stock compensation of $50 million. New revumenib data are expected in the fourth quarter of 2026. The Phase 2 MAXPIRe trial missed its primary endpoint, and Syndax does not plan further axatilimab development in idiopathic pulmonary fibrosis. Aaron Ondrey becomes chief financial officer November 9, 2026, following Keith Goldan’s decision to retire.
Syndax Pharmaceuticals (SNDX) announced that Revuforj received the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases. The Galien Foundation recognition concerns revumenib, a menin inhibitor approved for adults and children one year and older with certain relapsed or refractory acute leukemias, meaning cancers that returned or resisted treatment.
The FDA approved Revuforj in November 2024 for acute leukemia with a KMT2A translocation. In October 2025, approval expanded to acute myeloid leukemia with a susceptible NPM1 mutation in patients with no satisfactory alternative treatment options. Trials of revumenib are ongoing or planned, including combinations with standard treatments in newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger and management team members will participate in four November investor conferences.
Fireside chats are scheduled for November 10, 2026 at Guggenheim in Boston, November 12 at Stifel in New York, November 17 at UBS in London and November 19 at Jefferies in London. Live webcasts and limited-time replays will be available on the company’s investor website.
Syndax Pharmaceuticals (SNDX) will report third quarter 2026 financial results and provide a business update on November 2, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET that day. The webcast and accompanying slides will be accessible through the company's investor website. A replay will be available approximately 24 hours after the call and remain available for 90 days following the call.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that Revuforj (revumenib) was named to TIME’s Best Inventions of 2026 in Medical and Healthcare.
Revuforj is FDA approved for adults and children one year and older with relapsed or refractory acute leukemia with a KMT2A translocation, or acute myeloid leukemia with a susceptible NPM1 mutation and no satisfactory alternative treatment options. TIME evaluated contenders on originality, efficacy, ambition and impact.